Brock WJ - Search Results

1

Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.

Bassan A, Steigerwalt R, Keller D, Beilke L, Bradley PM, Bringezu F, Brock WJ, Burns-Naas LA, Chambers J, Cross K, Dorato M, Elespuru R, Fuhrer D, Hall F, Hartke J, Jahnke GD, Kluxen FM, McDuffie E, Schmidt F, Valentin JP, Woolley D, Zane D, Myatt GJ. Bassan A, et al. Among authors: brock wj. Front Toxicol. 2024 Apr 5;6:1370045. doi: 10.3389/ftox.2024.1370045. eCollection 2024. Front Toxicol. 2024. PMID: 38646442 Free PMC article.

2

A weight of evidence evaluation of the mode of action of isoeugenol.

Brock WJ, Greene T, Van Landingham C, Gentry R. Brock WJ, et al. Regul Toxicol Pharmacol. 2024 Jun;150:105642. doi: 10.1016/j.yrtph.2024.105642. Epub 2024 May 11. Regul Toxicol Pharmacol. 2024. PMID: 38735521

3

Species-differences in the in vitro biotransformation of trifluoroethene (HFO-1123).

Dekant R, Bertermann R, Serban J, Sharma S, Shinohara M, Morizawa Y, Okamoto H, Brock W, Dekant W, Mally A. Dekant R, et al. Arch Toxicol. 2023 Dec;97(12):3095-3111. doi: 10.1007/s00204-023-03603-3. Epub 2023 Oct 4. Arch Toxicol. 2023. PMID: 37792044 Free PMC article.

4

Correction: Species-differences in the in vitro biotransformation of trifluoroethene (HFO-1123).

Dekant R, Bertermann R, Serban J, Sharma S, Shinohara M, Morizawa Y, Okamoto H, Brock W, Dekant W, Mally A. Dekant R, et al. Arch Toxicol. 2024 Jan;98(1):363-364. doi: 10.1007/s00204-023-03640-y. Arch Toxicol. 2024. PMID: 38057564 Free PMC article. No abstract available.

5

Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats.

Tillman EJ, Brock WJ, Rolph T. Tillman EJ, et al. Among authors: brock wj. Br J Pharmacol. 2022 Apr;179(7):1384-1394. doi: 10.1111/bph.15725. Epub 2022 Jan 29. Br J Pharmacol. 2022. PMID: 34773249 Free PMC article.

6

Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.

Authier S, Brock WJ, Halpern W, Harris SN, Jones D, McGovern T, McGovern PD, Pugsley MK. Authier S, et al. Among authors: brock wj. Int J Toxicol. 2021 Dec;40(6):487-505. doi: 10.1177/10915818211043435. Epub 2021 Sep 25. Int J Toxicol. 2021. PMID: 34569357

7

Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity.

Beaudoin JJ, Brock WJ, Watkins PB, Brouwer KLR. Beaudoin JJ, et al. Among authors: brock wj. Clin Pharmacol Ther. 2021 Feb;109(2):433-442. doi: 10.1002/cpt.2007. Epub 2020 Sep 8. Clin Pharmacol Ther. 2021. PMID: 32748396 Free PMC article.

8

Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.

Bezençon J, Beaudoin JJ, Ito K, Fu D, Roth SE, Brock WJ, Brouwer KLR. Bezençon J, et al. Among authors: brock wj. Drug Metab Dispos. 2019 Aug;47(8):899-906. doi: 10.1124/dmd.119.086785. Epub 2019 Jun 3. Drug Metab Dispos. 2019. PMID: 31160314 Free PMC article.

9

Introduction to the WEEL values of selected fluorocarbons.

Brock WJ. Brock WJ. Toxicol Ind Health. 2019 Mar;35(3):177-179. doi: 10.1177/0748233719825532. Toxicol Ind Health. 2019. PMID: 30862295 No abstract available.

10

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Beaudoin JJ, Bezençon J, Cao Y, Mizuno K, Roth SE, Brock WJ, Brouwer KLR. Beaudoin JJ, et al. Among authors: brock wj. Drug Metab Dispos. 2019 Feb;47(2):155-163. doi: 10.1124/dmd.118.083907. Epub 2018 Nov 30. Drug Metab Dispos. 2019. PMID: 30504136 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters